MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Puma Biotechnology Accounts Receivables 2011-2026 | PBYI
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Puma Biotechnology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.7 M | 32 M | 47.8 M | 40.4 M | 32.5 M | 25.5 M | 28.9 M | 20.8 M | 9.67 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53.7 M | 9.67 M | 32.4 M |
Quarterly Accounts Receivables Puma Biotechnology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.6 M | 25.9 M | 25.2 M | 32 M | 54.6 M | 28.1 M | 24.6 M | 47.8 M | 29 M | 31.3 M | 31.2 M | 40.4 M | 28 M | - | 27 M | 32.5 M | 23.8 M | 30.5 M | 26.2 M | 25.5 M | 25.5 M | 25.5 M | 25.5 M | 28.9 M | 28.9 M | 28.9 M | 28.9 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | 9.67 M | 9.67 M | 9.67 M | 9.67 M | - | 1.18 M | 1.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54.6 M | 1.18 M | 25.4 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M |  USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Aptorum Group Limited
APM
|
62.2 K | $ 0.97 | 8.23 % | $ 7.13 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
98.7 M | $ 22.56 | 1.17 % | $ 3.74 B | USA |
 |
Aptinyx
APTX
|
257 K | - | -39.0 % | $ 4.57 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
312 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
2.76 M | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
9.8 M | - | - | $ 35.4 M | USA |
 |
ChromaDex Corporation
CDXC
|
9.74 M | - | -0.88 % | $ 598 M | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
1 M | - | 17.91 % | $ 11.1 M | USA |
 |
Aquestive Therapeutics
AQST
|
17.8 M | $ 4.1 | -0.12 % | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
146 M | $ 23.47 | 0.21 % | $ 2.99 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
24 M | $ 1.48 | 3.87 % | $ 394 M |  Britain |
 |
ImmuCell Corporation
ICCC
|
3.42 M | $ 8.25 | - | $ 74.5 M | USA |
 |
BeiGene, Ltd.
BGNE
|
865 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
300 K | - | - | $ 546 M | USA |
 |
Cardiff Oncology
CRDF
|
182 K | $ 1.73 | 0.72 % | $ 116 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
15.4 M | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
233 K | $ 1.06 | -2.55 % | $ 12.9 M | USA |